# 510(K) SUMMARY OF SAFETY AND EFFECTIVENESS

This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92.

The assigned 510(k) number is: K071591

# Establishment:

Response Biomedical Corporation 100-8900 Glenlyon Parkway Burnaby, British Columbia Canada, V5J 5J8

Tel: (604) 456-6010   
Fax: (604) 456-6066

Contact: Ken Pilgrim Director - Quality / Regulatory

Prepared: April 15, 2008

Regulatory Information: Trade Name: RAMP® Influenza A/B Assay Common Name: Influenza A/B immunological test system Classification Name: Influenza A/B immunological test system Regulation Number: 866.3330, Influenza virus serological reagents Classification: Class I Product Code: GNX Panel: Microbiology

# Predicate Device:

Immunoassay:

BinaxNOW® Influenza A & B Test, (K062109), which is currently marketed by Binax, Inc.

# Intended Use:

The RAMP® Influenza A/B Assay is a qualitative immunochromatographic assay used to identify the presence of Influenza A and Influenza B nucleoprotein antigens in nasal wash, nasal aspirate, nasopharyngeal aspirate, and nasopharyngeal swab specimens from symptomatic patients. It is an in vitro diagnostic assay that aids in the rapid differential diagnosis of influenza viral infections in symptomatic patients. A negative test is presumptive and it is recommended these results be confirmed by cel culture. Negative results do not preclude influenza virus infection and should not be used as the sole basis for treatment or other management decisions.

The test performance characteristics for Influenza B were established primarily with retrospective, frozen specimens. Users may wish to further evaluate the sensitivity performance of this test for Influenza B using fresh samples.

# Description of the Device:

The RAMP Influenza A/B Assay is a qualitative immunochromatographic test that utilizes the RAMP 200 for the differential determination of Influenza A and Influenza B in nasal wash, nasal aspirate, nasopharyngeal aspirate, and nasopharyngeal swab samples. A wash/aspirate or swab sample is added to the Sample Buffer. The Sample Buffer is optimized to improve binding of the anti-influenza antibodies to the nucleoprotein antigens and reduce non-specific binding and fluorescent signal background. This sample is then mixed using the Assay Tip containing fluorescent-dyed particles conjugated to specific antibodies and applied into the sample well of the Test Cartridge. The sample migrates along the strip. Fluorescent-dyed particles coated with anti-Influenza A and anti-Influenza B antibodies bind to Influenza A or B antigens, respectively, i present in the sample. As the sample migrates along the strip, Influenza-bound particles are captured at either the Influenza A or the Influenza B detection zone, and excess fluorescent-dyed particles are captured at the internal standard zone.

The instrument then measures the amount of fluorescence emitted by the complexes at the two detection zones (Influenza A and Influenza B) and at the internal standard zone.The instrument calculates a ratio (RAMP Ratio) using the fluorescence reading of each detection zone (A or B) and the internal standard zone. The instrument compares these ratios to pre-defined threshold limits to determine a positive or negative result for Influenza A and Influenza B in the tested sample.

# Comparison of Technological Characteristics:

The RAMP Influenza A/B Assay and BinaxNOW Influenza A & B Test are rapid immunochromatographic tests used for the detection of influenza virus antigen utilizing antibodies targeted toward the nucleoprotein (NP) of the virus and thus do not require viable virus particles for detection. The RAMP and BinaxNOW tests provide results in approximately 15 minutes. Viral cell culture relies on the growth of cll lines and their infection with virus contained in the clinical sample. The time required to get a definitive result using these culture methods can be up to 30 days depending on the samples and methods used.

The RAMP Influenza A/B Assay and BinaxNOW Influenza A & B Test are for use in the central laboratory, stat-lab and point-of-care facilities, while viral cell culture is for use in the central laboratories due to its requirement for specialized equipment and highly trained operators.

These methods are indicated for use in the differential determination of Influenza A and Influenza B in nasal wash/aspirate, nasopharyngeal aspirate, and nasopharyngeal swab samples.

# Summary of Studies:

# ANALYTICAL PERFORMANCE CHARACTERISTICS

# Assay Precision

The total intra-assay and inter-assay precision of the RAMP Influenza A/B Assay was evaluated using a panel consisting of high negative Influenza A, Influenza A LoD (Limit of Detection) positive, Influenza A 2x LoD positive, high negative Influenza B, Influenza B LoD positive, and Influenza B 2x LoD positive samples. The influenza strains used to prepare the samples were Influenza AHong Kong/8/68 and Influenza $B / L e \theta / 4 0$ following viral titer determinations. Multiple operators across multiple sites tested replicates of each sample on 5 different days. There was $100 \%$ (540/540) agreement with the expected test results for all specimens tested, with no significant differences within run (same operator on same day), between run, operators, or sites. The RAMP Flu A/B assay is a qualitative assay based on numerical RAMP Ratio values. The overall RAMP Ratio %CV across all sites ranged from $9 . 6 \%$ to $1 5 . 1 \%$ depending upon analyte type and concentration tested.

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>PanelMember ID</td><td rowspan=1 colspan=1>Influenza AHighNegative</td><td rowspan=1 colspan=1>Influenza ALowPositive</td><td rowspan=1 colspan=1>Influenza AMediumPositive</td><td rowspan=1 colspan=1>Influenza BHighNegative</td><td rowspan=1 colspan=1>Influenza BLowPositive</td><td rowspan=1 colspan=1>Influenza BMediumPositive</td><td rowspan=2 colspan=1>TotalAgreementAll (%)</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Viral Titer(EIDs/mL)</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>300</td><td rowspan=1 colspan=1>600</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>316</td><td rowspan=1 colspan=1>632</td></tr><tr><td rowspan=2 colspan=1>Site 1</td><td rowspan=1 colspan=1>AgreementwithExpectedresult</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>30/30</td><td rowspan=2 colspan=1>180/180(100%)</td></tr><tr><td rowspan=1 colspan=1>% CV</td><td rowspan=1 colspan=1>11.6%</td><td rowspan=1 colspan=1>6.3%</td><td rowspan=1 colspan=1>7.9%</td><td rowspan=1 colspan=1>16.4%</td><td rowspan=1 colspan=1>8.9%</td><td rowspan=1 colspan=1>7.9%</td></tr><tr><td rowspan=2 colspan=1>Site 2</td><td rowspan=1 colspan=1>AgreementwithExpectedresult</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>30/30</td><td rowspan=2 colspan=1>180/180(100%)</td></tr><tr><td rowspan=1 colspan=1>% CV</td><td rowspan=1 colspan=1>7.7%</td><td rowspan=1 colspan=1>8.1%</td><td rowspan=1 colspan=1>9.3%</td><td rowspan=1 colspan=1>15.6%</td><td rowspan=1 colspan=1>9.5%</td><td rowspan=1 colspan=1>7.0%</td></tr><tr><td rowspan=2 colspan=1>Site 3</td><td rowspan=1 colspan=1>AgreementwithExpectedresult</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>30/30</td><td rowspan=2 colspan=1>180/180100%)</td></tr><tr><td rowspan=1 colspan=1>% CV</td><td rowspan=1 colspan=1>14.5%</td><td rowspan=1 colspan=1>9.9%</td><td rowspan=1 colspan=1>13.5%</td><td rowspan=1 colspan=1>11.3%</td><td rowspan=1 colspan=1>9.5%</td><td rowspan=1 colspan=1>10.5%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>TotalAgreementwithExpectedresult</td><td rowspan=1 colspan=1>90/90(100%)</td><td rowspan=1 colspan=1>90/90(100%)</td><td rowspan=1 colspan=1>90/90(100%)</td><td rowspan=1 colspan=1>90/90(100%)</td><td rowspan=1 colspan=1>90/90(100%)</td><td rowspan=1 colspan=1>90/90(100%)</td><td rowspan=1 colspan=1>540/540(100%)</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>95% CI</td><td rowspan=1 colspan=1>96%-100%</td><td rowspan=1 colspan=1>96%-100%</td><td rowspan=1 colspan=1>96%-100%</td><td rowspan=1 colspan=1>96%-100%</td><td rowspan=1 colspan=1>96%-100%</td><td rowspan=1 colspan=1>96%-100%</td><td rowspan=1 colspan=1>99%-100%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Overall% CV</td><td rowspan=1 colspan=1>11.9%</td><td rowspan=1 colspan=1>10.4%</td><td rowspan=1 colspan=1>12.6%</td><td rowspan=1 colspan=1>15.1%</td><td rowspan=1 colspan=1>10.6%</td><td rowspan=1 colspan=1>9.6%</td><td rowspan=1 colspan=1></td></tr></table>

# Analytical Sensitivity

The RAMP Influenza $A / B$ Assay was evaluated for analytical sensitivity after viral titer was determined by testing 2 strains of Influenza A (Hong Kong/8/68 and PR/8/34) and 2 strains of Influenza B $( L e e / 4 0$ and $A | | \mathsf { e n } / 4 5 \rangle$ at the Limit of Detection (LoD) concentration, the cut-off concentration, and at a high negative concentration in either VTM (Viral Transport Medium, to simulate a swab sample type) or PBs (Phosphate Buffered Saline, to simulate a wash sample type). Although the specific influenza strains causing infection in humans can vary year to year, all contain the conserved nucleoproteins targeted by the RAMP Influenza A/B Assay.1Analytical sensitivity (LoD) ranged from 3.0x10² to 6.4x10² EIDso/mL for the Influenza A strains and 2.8x102 to $7 . 1 \times 1 0 ^ { 4 } E 1 0 _ { 5 0 } / \mathrm { m L }$ for the Influenza B strains in VTM and PBS.

<table><tr><td rowspan=1 colspan=1>Viral Strain</td><td rowspan=1 colspan=1>LoD Concentration</td></tr><tr><td rowspan=1 colspan=1>Influenza A/Hong Kong/8/68 (H3N2),ATCC VR-544 in VTM</td><td rowspan=1 colspan=1>3.0 X 10²2 EID50/mL</td></tr><tr><td rowspan=1 colspan=1>Influenza A/Hong Kong/8/68 (H3N2),ATCC VR-544 in PBS</td><td rowspan=1 colspan=1>5.0 X 102 EID50/mL</td></tr><tr><td rowspan=1 colspan=1>Influenza A/PR/8/34 (H1N1),ATCC VR-95 in VTM</td><td rowspan=1 colspan=1>2.0 X 10²2 EID50/mL</td></tr><tr><td rowspan=1 colspan=1>Influenza A/PR/8/34 (H1N1),ATCC VR-95 in PBS</td><td rowspan=1 colspan=1>6.4 X 10^²2 EID50/mL</td></tr><tr><td rowspan=1 colspan=1>Influenza B/Lee/40,ATCC VR-101 in VTM</td><td rowspan=1 colspan=1>3.2 X 10^²2 EID50/mL</td></tr><tr><td rowspan=1 colspan=1>Influenza B/Lee/40,ATCC VR-101 in PBS</td><td rowspan=1 colspan=1>2.8 X 10² EID50/mL</td></tr><tr><td rowspan=1 colspan=1>Influenza B/Allen/45,ATCC VR-102 in VTM</td><td rowspan=1 colspan=1>5.3 X 104 EID50/mL</td></tr><tr><td rowspan=1 colspan=1>Influenza B/Allen/45,ATCC VR-102 in PBS</td><td rowspan=1 colspan=1>7.1 X 104 EID50/mL</td></tr></table>

# Analytical Reactivity

The RAMP Influenza A/B Assay was evaluated for analytical reactivity by testing 5 strains of Influenza A (FM/1/47, NWS/33, New Jersey/8/76, Aichi/2/68, and Victoria/3/75) and 3 strains of Influenza B (GL/1739/54, Taiwan/2/62, and Hong Kong/5/72) prepared in VTM at concentrations that would consistently give positive results. Five (5) replicates were tested for each viral strain. The viral titers of these influenza strains were determined prior to analytical sensitivity testing. Analytical reactivity was established for the 5 Influenza A and 3 Influenza B strains tested. The concentrations for reactivity ranged from $3 . 0 \times 1 0 ^ { 2 }$ to $3 . 0 \times 1 0 ^ { 3 } \in 1 0 . 5 0 / m L$ for the Influenza A strains and $1 . 6 \times 1 0 ^ { 1 }$ to $9 . 5 \times 1 0 ^ { 3 } E 1 \dot { \mathsf { D } } _ { 5 0 } / \mathsf { m L }$ for the Influenza B strains.

<table><tr><td rowspan=1 colspan=1>Strain</td><td rowspan=1 colspan=1>ReactivityConcentration</td><td rowspan=1 colspan=1>RAMP Result</td></tr><tr><td rowspan=1 colspan=1>Influenza A/FM/1/47 (H1N1)ATCC VR-97</td><td rowspan=1 colspan=1>3.0 X 10EID50/mL</td><td rowspan=1 colspan=1>100% Flu A Positive</td></tr><tr><td rowspan=1 colspan=1>Influenza A/NWS/33 (H1N1)ATCC VR-219</td><td rowspan=1 colspan=1>3.0 X 10^²2 EIDso/mL</td><td rowspan=1 colspan=1>100% Flu A Positive</td></tr><tr><td rowspan=1 colspan=1>Influenza A/New Jersey/8/76(H1N1), ATCC VR-897</td><td rowspan=1 colspan=1>3.0 X 102EID50/mL</td><td rowspan=1 colspan=1>100% Flu A Positive</td></tr><tr><td rowspan=1 colspan=1>Influenza A/Aichi/2/68 (H3N2)ATCC VR-547</td><td rowspan=1 colspan=1>9.0 X 10²2 EIDso/mL</td><td rowspan=1 colspan=1>100% Flu A Positive</td></tr><tr><td rowspan=1 colspan=1>Influenza A/Victoria/3/75(H3N2), ATCC VR-822</td><td rowspan=1 colspan=1>9.0 X 10^²2 EID50/mL</td><td rowspan=1 colspan=1>100% Flu A Positive</td></tr><tr><td rowspan=1 colspan=1>Influenza B/GL/1739/54ATCC VR-103</td><td rowspan=1 colspan=1>9.5 X 103 EID50/mL</td><td rowspan=1 colspan=1>100% Flu B Positive</td></tr><tr><td rowspan=1 colspan=1>Influenza B/Taiwan/2/62ATCC VR-295</td><td rowspan=1 colspan=1>1.6 X 10&#x27;1 EID50/mL</td><td rowspan=1 colspan=1>100% Flu B Positive</td></tr><tr><td rowspan=1 colspan=1>Influenza B/Hong Kong/5/72ATCC VR-823</td><td rowspan=1 colspan=1>6.3 X 10³3EID50/mL</td><td rowspan=1 colspan=1>100% Flu B Positive</td></tr></table>

# Analytical Specificity (Potential Cross-Reactive Organisms)

The analytical specificity of the RAMP Influenza $A / B$ Assay was determined by testing a panel consisting of 15 viruses and 17 bacteria that may be present in the nasal cavity or nasopharynx. Viral and bacterial isolates were tested at the concentrations listed after titer determination at $n = 3$ replicates each. None of the organisms tested gave a positive result in the RAMP Influenza A/B Assay. Note: RAMP Influenza A/B Assay potential cross-reactivity with Chlamydophilia preumoniae has not been determined.

Specificity; Potential Cross-Reactive Substances   

<table><tr><td colspan="1" rowspan="1">Strain/Isolate</td><td colspan="1" rowspan="1">Concentration</td><td colspan="1" rowspan="1">RAMP Flu Aresult</td><td colspan="1" rowspan="1">RAMP Flu Bresult</td></tr><tr><td colspan="1" rowspan="1">Adenovirus, Type 1</td><td colspan="1" rowspan="1">105 TCID50/mL</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Adenovirus, Type 7a</td><td colspan="1" rowspan="1">105.15 TCIDso/mL</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Respiratory Syncytial Virus (RSV)</td><td colspan="1" rowspan="1">$10 TCIDso/mL</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Human coronavirus, strain OC43</td><td colspan="1" rowspan="1">$10^ TCID5o/mL</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Human coronavirus Strain 229E</td><td colspan="1" rowspan="1">105.23TCID50/mL</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Cytomegalovirus</td><td colspan="1" rowspan="1">$10 5.155TCID50/mL</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Enterovirus, Type 71</td><td colspan="1" rowspan="1">105.15TCID5o/mL</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Epstein Barr Virus</td><td colspan="1" rowspan="1">10 TCID5o/mL</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Measles</td><td colspan="1" rowspan="1">$10^ TCIDso/mL</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Mumps virus</td><td colspan="1" rowspan="1">10 TCID50/mL</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Human Parainfluenza, Type 1</td><td colspan="1" rowspan="1">104.75 TCID5o/mL</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Human Parainfluenza, Type 2</td><td colspan="1" rowspan="1">$105 TCID5o/mL</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Human Parainfluenza, Type 3</td><td colspan="1" rowspan="1">$10^5 TCIDso/mL</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Human metapneumovirus</td><td colspan="1" rowspan="1">$10^ TCIDso/mL</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Human Rhinovirus, Strain 1A</td><td colspan="1" rowspan="1">10 TCID5o/mL</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Bordetella pertussis</td><td colspan="1" rowspan="1">10^ cfu/mL</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Corynebacterium Sp.</td><td colspan="1" rowspan="1">10^ cfu/mL</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Escherichia coli</td><td colspan="1" rowspan="1">10^ cfu/mL</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Haemophilus influenzae</td><td colspan="1" rowspan="1">$10^ cfu/mL</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Lactobacillus casei</td><td colspan="1" rowspan="1">10^  cfu/mL</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Legionella pneumophila</td><td colspan="1" rowspan="1">$10^ cfu/mL</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Moraxella catarrhalis</td><td colspan="1" rowspan="1">$10^ cfu/mL</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Mycobacterium tuberculosis avirulent</td><td colspan="1" rowspan="1">$10^ cfu/mL</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Mycoplasma pneumoniae</td><td colspan="1" rowspan="1">$10^ $ cfu/mL</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Neisseria menigitidis</td><td colspan="1" rowspan="1">$10^ }cfu/mL</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Neisseria sicca</td><td colspan="1" rowspan="1">106}cfu/mL</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Psudomonas aeruginosa</td><td colspan="1" rowspan="1">10 cfu/mL</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Streptococcus pneumoniae</td><td colspan="1" rowspan="1">$10^ cfu/ml</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Streptococcus pyogenes (Group A)</td><td colspan="1" rowspan="1">$10^ cfu/mL</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Streptococcus salivarius</td><td colspan="1" rowspan="1">10 cfu/mL</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Staphylococcus epidermidis</td><td colspan="1" rowspan="1">10 cfu/mL</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Staphylococcus aureus (Protein Aproducer)</td><td colspan="1" rowspan="1">106 cfu/mL</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">Negative</td></tr></table>

# Interference

Whole blood and a number of other potentially interfering substances (medications and over the counter (OTC) products) that may be present naturally or artificially introduced in the nasal cavity or nasopharynx were evaluated in the RAMP Influenza A/B Assay. The substances were added to a negative sample (viral transport media), an Influenza A LoD positive sample, an Influenza A 2x LoD positive sample, an Influenza B LoD positive sample and an Influenza B 2x LoD positive sample and tested in the RAMP Influenza AB Assay. The influenza strains used to prepare the samples were Influenza A/Hong Kong/8/68 and Influenza B/Lee/40 following titer determination. There was 100% agreement with expected results for all replicates (for n=3 replicates tested). None of the substances tested at the concentrations indicated interfered with the test results of negative and positive influenza samples in the RAMP Influenza A/B Assay. The RAMP Flu AB assay is a qualitative assay based on numerical RAMP Ratio values. The Percent of Mean Control Ratio values were calculated using these RAMP Ratios.

# Interfering Substances Study Results

<table><tr><td colspan="1" rowspan="2">Substance Tested</td><td colspan="1" rowspan="2">Conc.Tested</td><td colspan="5" rowspan="1">RAMP Results: Percent of Mean Control Ratio</td></tr><tr><td colspan="1" rowspan="1">NegativeFluA/Flu B</td><td colspan="1" rowspan="1">Influenza ALoD</td><td colspan="1" rowspan="1">Influenza A2x LoD</td><td colspan="1" rowspan="1">Influenza 8LoD</td><td colspan="1" rowspan="1">Influenza B2x LoD</td></tr><tr><td colspan="1" rowspan="1">Contral(No interferingsubstance)</td><td colspan="1" rowspan="1">NotApplicable</td><td colspan="1" rowspan="1">100% / 100%</td><td colspan="1" rowspan="1">100%</td><td colspan="1" rowspan="1">100%</td><td colspan="1" rowspan="1">100%</td><td colspan="1" rowspan="1">100%</td></tr><tr><td colspan="1" rowspan="1">NegativeFluA/FluB</td><td colspan="1" rowspan="1">Influenza ALOD</td><td colspan="1" rowspan="1">Influenza A2LOD</td><td colspan="1" rowspan="1">Influenza BLoD</td><td colspan="1" rowspan="1">Influenza B2x LoD</td></tr><tr><td colspan="1" rowspan="1">Fisherman's FriendThroat Drop</td><td colspan="1" rowspan="1">15% w/v</td><td colspan="1" rowspan="1">120% / 105%</td><td colspan="1" rowspan="1">101%</td><td colspan="1" rowspan="1">103%</td><td colspan="1" rowspan="1">99%</td><td colspan="1" rowspan="1">120%</td></tr><tr><td colspan="1" rowspan="1">Halls Throat Drop</td><td colspan="1" rowspan="1">15% w/v</td><td colspan="1" rowspan="1">96% / 104%</td><td colspan="1" rowspan="1">101%</td><td colspan="1" rowspan="1">111%</td><td colspan="1" rowspan="1">91%</td><td colspan="1" rowspan="1">111%</td></tr><tr><td colspan="1" rowspan="1">Cepacol Throat Drop</td><td colspan="1" rowspan="1">15% w/v</td><td colspan="1" rowspan="1">91% /101%</td><td colspan="1" rowspan="1">98%</td><td colspan="1" rowspan="1">101%</td><td colspan="1" rowspan="1">105%</td><td colspan="1" rowspan="1">118%</td></tr><tr><td colspan="1" rowspan="1">4-Acetamidophenol</td><td colspan="1" rowspan="1">10 mg/mL</td><td colspan="1" rowspan="1">110% /117%</td><td colspan="1" rowspan="1">99%</td><td colspan="1" rowspan="1">100%</td><td colspan="1" rowspan="1">104%</td><td colspan="1" rowspan="1">117%</td></tr><tr><td colspan="1" rowspan="1">Acetylsalicylic Acid</td><td colspan="1" rowspan="1">15 mg/mL</td><td colspan="1" rowspan="1">89% / 106%</td><td colspan="1" rowspan="1">98%</td><td colspan="1" rowspan="1">97%</td><td colspan="1" rowspan="1">110%</td><td colspan="1" rowspan="1">118%</td></tr><tr><td colspan="1" rowspan="1">Chloropheniramine</td><td colspan="1" rowspan="1">5 mg/mL</td><td colspan="1" rowspan="1">107% / 110%</td><td colspan="1" rowspan="1">101%</td><td colspan="1" rowspan="1">95%</td><td colspan="1" rowspan="1">112%</td><td colspan="1" rowspan="1">118%</td></tr><tr><td colspan="1" rowspan="1">DiphenyIhydramine</td><td colspan="1" rowspan="1">5 mg/mL</td><td colspan="1" rowspan="1">109% / 126%</td><td colspan="1" rowspan="1">99%</td><td colspan="1" rowspan="1">100%</td><td colspan="1" rowspan="1">115%</td><td colspan="1" rowspan="1">116%</td></tr><tr><td colspan="1" rowspan="1">PhenylpropanolamineHCI</td><td colspan="1" rowspan="1">20 mg/mL</td><td colspan="1" rowspan="1">126% / 100%</td><td colspan="1" rowspan="1">91%</td><td colspan="1" rowspan="1">96%</td><td colspan="1" rowspan="1">113%</td><td colspan="1" rowspan="1">113%</td></tr><tr><td colspan="1" rowspan="1">OseltamivIr Phosphate{Tamiflu}</td><td colspan="1" rowspan="1">50 mg/mL</td><td colspan="1" rowspan="1">106% / 101%</td><td colspan="1" rowspan="1">105%</td><td colspan="1" rowspan="1">105%</td><td colspan="1" rowspan="1">106%</td><td colspan="1" rowspan="1">111%</td></tr><tr><td colspan="1" rowspan="1">Rimantadine HCI</td><td colspan="1" rowspan="1">500 ng/mL</td><td colspan="1" rowspan="1">103% / 103%</td><td colspan="1" rowspan="1">105%</td><td colspan="1" rowspan="1">94%</td><td colspan="1" rowspan="1">111%</td><td colspan="1" rowspan="1">113%</td></tr><tr><td colspan="1" rowspan="1">Ribavirin (Rebetol)</td><td colspan="1" rowspan="1">100 mg/mL</td><td colspan="1" rowspan="1">137% / 136%</td><td colspan="1" rowspan="1">111%</td><td colspan="1" rowspan="1">106%</td><td colspan="1" rowspan="1">118%</td><td colspan="1" rowspan="1">120%</td></tr><tr><td colspan="1" rowspan="1">Good and KindMouthwash</td><td colspan="1" rowspan="1">20% v/v</td><td colspan="1" rowspan="1">97% / 118%</td><td colspan="1" rowspan="1">97%</td><td colspan="1" rowspan="1">106%</td><td colspan="1" rowspan="1">99%</td><td colspan="1" rowspan="1">125%</td></tr><tr><td colspan="1" rowspan="1">Cepacol Mouth Wash</td><td colspan="1" rowspan="1">20% v/v</td><td colspan="1" rowspan="1">88% / 85%</td><td colspan="1" rowspan="1">103%</td><td colspan="1" rowspan="1">104%</td><td colspan="1" rowspan="1">98%</td><td colspan="1" rowspan="1">118%</td></tr><tr><td colspan="1" rowspan="1">Scope Mouthwash</td><td colspan="1" rowspan="1">20% v/v</td><td colspan="1" rowspan="1">88% / 99%</td><td colspan="1" rowspan="1">96%</td><td colspan="1" rowspan="1">94%</td><td colspan="1" rowspan="1">98%</td><td colspan="1" rowspan="1">112%</td></tr><tr><td colspan="1" rowspan="1">Rhinocort Nasal Spray</td><td colspan="1" rowspan="1">15% v/v</td><td colspan="1" rowspan="1">85% / 88%</td><td colspan="1" rowspan="1">109%</td><td colspan="1" rowspan="1">101%</td><td colspan="1" rowspan="1">90%</td><td colspan="1" rowspan="1">122%</td></tr><tr><td colspan="1" rowspan="1">Nasonex Nasal Spray</td><td colspan="1" rowspan="1">15% v/v</td><td colspan="1" rowspan="1">104% / 90%</td><td colspan="1" rowspan="1">103%</td><td colspan="1" rowspan="1">106%</td><td colspan="1" rowspan="1">92%</td><td colspan="1" rowspan="1">113%</td></tr><tr><td colspan="1" rowspan="1">Flonase Nasal Spray</td><td colspan="1" rowspan="1">15% v/v</td><td colspan="1" rowspan="1">103% / 104%</td><td colspan="1" rowspan="1">109%</td><td colspan="1" rowspan="1">100%</td><td colspan="1" rowspan="1">95%</td><td colspan="1" rowspan="1">113%</td></tr><tr><td colspan="1" rowspan="1">Oxymetazoline HCI</td><td colspan="1" rowspan="1">0.05% v/v</td><td colspan="1" rowspan="1">116% /95%</td><td colspan="1" rowspan="1">101%</td><td colspan="1" rowspan="1">103%</td><td colspan="1" rowspan="1">97%</td><td colspan="1" rowspan="1">108%</td></tr><tr><td colspan="1" rowspan="1">Phenylephrine HCI</td><td colspan="1" rowspan="1">10 mg/mL</td><td colspan="1" rowspan="1">126% / 119%</td><td colspan="1" rowspan="1">101%</td><td colspan="1" rowspan="1">99%</td><td colspan="1" rowspan="1">106%</td><td colspan="1" rowspan="1">117%</td></tr><tr><td colspan="1" rowspan="1">Guaiacol Glycerol Ether(Benylin)</td><td colspan="1" rowspan="1">20 mg/mL</td><td colspan="1" rowspan="1">166% / 153%</td><td colspan="1" rowspan="1">118%</td><td colspan="1" rowspan="1">113%</td><td colspan="1" rowspan="1">118%</td><td colspan="1" rowspan="1">124%</td></tr><tr><td colspan="1" rowspan="1">Dextromethorphan</td><td colspan="1" rowspan="1">2 mg/mL</td><td colspan="1" rowspan="1">95% / 101%</td><td colspan="1" rowspan="1">115%</td><td colspan="1" rowspan="1">115%</td><td colspan="1" rowspan="1">126%</td><td colspan="1" rowspan="1">134%</td></tr><tr><td colspan="1" rowspan="1">Salbutamol Sulfate</td><td colspan="1" rowspan="1">400 ng/mL</td><td colspan="1" rowspan="1">102% / 92%</td><td colspan="1" rowspan="1">98%</td><td colspan="1" rowspan="1">99%</td><td colspan="1" rowspan="1">111%</td><td colspan="1" rowspan="1">116%</td></tr><tr><td colspan="1" rowspan="1">NegativeFluA/FluB</td><td colspan="1" rowspan="1">Influenza ALOD</td><td colspan="1" rowspan="1">Influenza A2x LoD</td><td colspan="1" rowspan="1">Influenza BLoD</td><td colspan="1" rowspan="1">Influenza B2x LoD</td></tr><tr><td colspan="1" rowspan="1">Whole Blood*</td><td colspan="1" rowspan="1">2% v/v</td><td colspan="1" rowspan="1">126% /91%</td><td colspan="1" rowspan="1">75%</td><td colspan="1" rowspan="1">90%</td><td colspan="1" rowspan="1">106%</td><td colspan="1" rowspan="1">98%</td></tr></table>

A waring is added to the package insert to reflect that samples contaminated wih whole blood in greater concentrations (visibly bloody samples) may interfere in the interpretation of the assay.

# Transport Media

Six commercially available and two clinical-site-prepared transport media were evaluated for compatibility in the RAMP Influenza AB Assay by testing a negative sample (transport media only), an Influenza A LoD positive sample, an Influenza A 2x LoD positive sample, an Influenza B LoD positive sample, and an Influenza B 2x LoD positive sample in the RAMP Influenza AB Assay. The influenza strains used to prepare the samples were Influenza A/Hong Kong/8/68 and Influenza B/Lee/40 following titer determination. The RAMP Flu AB assay is a qualitative assay based on numerical RAMP Ratio values. The %CVs were calculated for the RAMP Ratios. None of the tested transport media interfered with the performance of the RAMP Influenza AB Assay.

<table><tr><td rowspan=2 colspan=1>Transport MediaTested</td><td rowspan=1 colspan=5>RAMP Results</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Influenza ALoD</td><td rowspan=1 colspan=1>Influenza A2x LoD</td><td rowspan=1 colspan=1>Influenza BLoD</td><td rowspan=1 colspan=1>Influenza B2x LoD</td></tr><tr><td rowspan=1 colspan=1>Copan UniversalTransport MediaUTM)</td><td rowspan=1 colspan=1>100% Neg</td><td rowspan=1 colspan=1>100%Flu A Pos</td><td rowspan=1 colspan=1>100%Flu A Pos</td><td rowspan=1 colspan=1>100%Flu B Pos</td><td rowspan=1 colspan=1>100%Flu B Pos</td></tr><tr><td rowspan=1 colspan=1>Remel M4 Media</td><td rowspan=1 colspan=1>100% Neg</td><td rowspan=1 colspan=1>100%Flu A Pos</td><td rowspan=1 colspan=1>100%Flu A Pos</td><td rowspan=1 colspan=1>100%Flu B Pos</td><td rowspan=1 colspan=1>100%Flu B Pos</td></tr><tr><td rowspan=1 colspan=1>Remel M4-RTMedia</td><td rowspan=1 colspan=1>100% Neg</td><td rowspan=1 colspan=1>100%Flu A Pos</td><td rowspan=1 colspan=1>100%Flu A Pos</td><td rowspan=1 colspan=1>100%Flu B Pos</td><td rowspan=1 colspan=1>100%Flu B Pos</td></tr><tr><td rowspan=1 colspan=1>Remel M5 Media</td><td rowspan=1 colspan=1>100% Neg</td><td rowspan=1 colspan=1>100%Flu A Pos</td><td rowspan=1 colspan=1>100%Flu A Pos</td><td rowspan=1 colspan=1>100%Flu B Pos</td><td rowspan=1 colspan=1>100%Flu B Pos</td></tr><tr><td rowspan=1 colspan=1>Starplex TransportMedia</td><td rowspan=1 colspan=1>100% Neg</td><td rowspan=1 colspan=1>100%Flu A Pos</td><td rowspan=1 colspan=1>100%Flu A Pos</td><td rowspan=1 colspan=1>100%Flu B Pos</td><td rowspan=1 colspan=1>100%Flu B Pos</td></tr><tr><td rowspan=1 colspan=1>PhosphateBuffered Saline(PBS) Solution</td><td rowspan=1 colspan=1>100% Neg</td><td rowspan=1 colspan=1>100%Flu A Pos</td><td rowspan=1 colspan=1>100%Flu A Pos</td><td rowspan=1 colspan=1>100%Flu B Pos</td><td rowspan=1 colspan=1>100%Flu B Pos</td></tr><tr><td rowspan=1 colspan=1>Site B In-houseMedia</td><td rowspan=1 colspan=1>100% Neg</td><td rowspan=1 colspan=1>100%Flu A Pos</td><td rowspan=1 colspan=1>100%Flu A Pos</td><td rowspan=1 colspan=1>100%Flu B Pos</td><td rowspan=1 colspan=1>100%Flu B Pos</td></tr><tr><td rowspan=1 colspan=1>Site A In-houseMedia</td><td rowspan=1 colspan=1>100% Neg</td><td rowspan=1 colspan=1>100%Flu A Pos</td><td rowspan=1 colspan=1>100%Flu A Pos</td><td rowspan=1 colspan=1>100%Flu B Pos</td><td rowspan=1 colspan=1>100%Flu B Pos</td></tr><tr><td rowspan=1 colspan=1>RAMP Ratio % CV</td><td rowspan=1 colspan=1>Flu A 19%Flu B 13%</td><td rowspan=1 colspan=1>4%</td><td rowspan=1 colspan=1>9%</td><td rowspan=1 colspan=1>7%</td><td rowspan=1 colspan=1>11%</td></tr></table>

# Sample Collection Swabs

Four swab materials were evaluated for compatibility in the RAMP Influenza A/B Assay by testing a negative sample (swab alone with no virus present), an Influenza A low positive sample (LoD), an Influenza A positive sample $( 2 x \ L 0 D )$ , an Influenza B low positive sample (LoD), and an Influenza B positive sample $( 2 \times \mathsf { L o D } )$ in the RAMP Influenza A/B Assay. The Flu strains used to prepare the samples were Influenza A/Hong Kong/8/68 and Influenza B/Lee/40 following titer determination. Each swab was dosed with the appropriate sample and extracted into Copan Universal Transport media prior to testing in the RAMP Influenza A/B Assay. The RAMP Flu AB assay is a qualitative assay based on numerical RAMP Ratio values. The $\% C V s$ were calculated based on the RAMP Ratios for the testing. The negative sample (swab alone) tested negative. At least $67 \%$ of each swab type inoculated with Influenza A or Influenza B at the LoD tested positive for the virus.

Note: In general, calcium alginate swabs are not recommended because they may be cytotoxic to cells and cause viral culture assay inhibition..

<table><tr><td rowspan=2 colspan=1>Swab Material Tested</td><td rowspan=1 colspan=5>RAMP Results</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Influenza ALoD</td><td rowspan=1 colspan=1>Influenza A2x LoD</td><td rowspan=1 colspan=1>Influenza BLoD</td><td rowspan=1 colspan=1>Influenza B2x LoD</td></tr><tr><td rowspan=1 colspan=1>Foam</td><td rowspan=1 colspan=1>100% Neg</td><td rowspan=1 colspan=1>100%Flu A Pos</td><td rowspan=1 colspan=1>100%Flu A Pos</td><td rowspan=1 colspan=1>100%Flu B Pos</td><td rowspan=1 colspan=1>100%Flu B Pos</td></tr><tr><td rowspan=1 colspan=1>Polyester</td><td rowspan=1 colspan=1>100% Neg</td><td rowspan=1 colspan=1>67%Flu A Pos</td><td rowspan=1 colspan=1>100%Flu A Pos</td><td rowspan=1 colspan=1>67 %Flu B Pos</td><td rowspan=1 colspan=1>100%Flu B Pos</td></tr><tr><td rowspan=1 colspan=1>Rayon</td><td rowspan=1 colspan=1>100% Neg</td><td rowspan=1 colspan=1>100%Flu A Pos</td><td rowspan=1 colspan=1>100%Flu A Pos</td><td rowspan=1 colspan=1>67 %Flu B Pos</td><td rowspan=1 colspan=1>100%Flu B Pos</td></tr><tr><td rowspan=1 colspan=1>Nylon</td><td rowspan=1 colspan=1>100% Neg</td><td rowspan=1 colspan=1>100%Flu A Pos</td><td rowspan=1 colspan=1>100%Flu A Pos</td><td rowspan=1 colspan=1>100%Flu B Pos</td><td rowspan=1 colspan=1>100%Flu B Pos</td></tr><tr><td rowspan=1 colspan=1>RAMP Ratio % CV</td><td rowspan=1 colspan=1>Flu A 17%Flu B 22%</td><td rowspan=1 colspan=1>15%</td><td rowspan=1 colspan=1>8%</td><td rowspan=1 colspan=1>29%</td><td rowspan=1 colspan=1>24%</td></tr></table>

# CLINICAL PERFORMANCE

# Method Comparison

The performance of the RAMP Influenza A/B Assay was compared to cell culture in a prospective study conducted as part of a multi-center trial in North America during the 2006-2007 influenza season when influenza A/H3 $( 3 6 . 5 \% )$ and A/H1 $( 6 3 . 5 \% )$ were the predominant Influenza A viruses in circulation.³ Four independent laboratories (located in distinct geographic regions) evaluated the RAMP Influenza A/B Assay in parallel with cell culture. Eight hundred forty-four (844) fresh specimens (nasal wash/aspirate, nasopharyngeal aspirate, or nasopharyngeal swab samples) prospectively collected during the 2006-2007 influenza season were tested. Across the sites these samples were drawn from an approximately equal mix of pediatric (0 - 21 years) and adult patients $( 2 1 +$ years) with approximately equal numbers of male and female patients. The mean (standard deviation) age of the patients was 28.6 (30.7) years. In order to supplement the prospective study, performance of the RAMP Influenza AB Test was also evaluated by two independent laboratories comparing to the original cell culture testing results (cell culture testing was performed using fresh specimens) on 75 retrospective frozen clinical nasopharyngeal swab samples and 130 retrospective frozen clinical wash/aspirate samples.

# Prospective Testing

Sensitivity and Specificity by Age Relative to Culture $\twoheadrightarrow$ Fresh Nasopharyngeal Swab; Age 0-5   

<table><tr><td rowspan=1 colspan=1>Prospective FreshNasopharyngealSwab(Age 0-5)</td><td rowspan=1 colspan=3>RAMP Influenza A</td><td rowspan=1 colspan=3>RAMP Influenza B</td></tr><tr><td rowspan=1 colspan=1>Tissue Culture</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>187</td><td rowspan=1 colspan=1>199</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>204</td><td rowspan=1 colspan=1>210</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>23</td><td rowspan=1 colspan=1>188</td><td rowspan=1 colspan=1>211</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>204</td><td rowspan=1 colspan=1>211</td></tr><tr><td rowspan=1 colspan=1>nmaGYlow</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>95% CI</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>95% CI</td></tr><tr><td rowspan=1 colspan=1>Sensitivity</td><td rowspan=1 colspan=1>11/12</td><td rowspan=1 colspan=1>91.7%</td><td rowspan=1 colspan=1>61.5-99.8%</td><td rowspan=1 colspan=1>1/1</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>NA</td></tr><tr><td rowspan=1 colspan=1>Specificity</td><td rowspan=1 colspan=1>187/199</td><td rowspan=1 colspan=1>94.0%</td><td rowspan=1 colspan=1>89.7-96.8%</td><td rowspan=1 colspan=1>204/210</td><td rowspan=1 colspan=1>97.1%</td><td rowspan=1 colspan=1>93.9-98.9%</td></tr></table>

Sensitivity and Specificity by Age Relative to Culture - Fresh Nasopharyngeal Swab; Age 6-21   

<table><tr><td rowspan=1 colspan=1>Prospective FreshNasopharyngealSwab(Age 6-21)</td><td rowspan=1 colspan=3>RAMP Influenza A</td><td rowspan=1 colspan=3>RAMP Influenza B</td></tr><tr><td rowspan=1 colspan=1>Tissue Culture</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>4</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>66</td><td rowspan=1 colspan=1>70</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>77</td><td rowspan=1 colspan=1>81</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>69</td><td rowspan=1 colspan=1>85</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>79</td><td rowspan=1 colspan=1>85</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>95% CI</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>95% CI</td></tr><tr><td rowspan=1 colspan=1>Sensitivity</td><td rowspan=1 colspan=1>12/15</td><td rowspan=1 colspan=1>80.0%</td><td rowspan=1 colspan=1>51.9-95.7%</td><td rowspan=1 colspan=1>214</td><td rowspan=1 colspan=1>50.0%</td><td rowspan=1 colspan=1>6.8-93.2%</td></tr><tr><td rowspan=1 colspan=1>Specificity</td><td rowspan=1 colspan=1>66/70</td><td rowspan=1 colspan=1>94.3%</td><td rowspan=1 colspan=1>86.0-98.4%</td><td rowspan=1 colspan=1>77/81</td><td rowspan=1 colspan=1>95.1%</td><td rowspan=1 colspan=1>87.8-98.6%</td></tr></table>

Sensitivity and Specificity by Age Relative to Culture $\twoheadrightarrow$ Fresh Nasopharyngeal Swab; Age 22-59   

<table><tr><td rowspan=1 colspan=1>Prospective FreshNasopharyngealSwab(Age 22-59)</td><td rowspan=1 colspan=3>RAMP Influenza A</td><td rowspan=1 colspan=3>RAMP Influenza B</td></tr><tr><td rowspan=1 colspan=1>Tissue Culture</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>23</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>4</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>136</td><td rowspan=1 colspan=1>137</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>155</td><td rowspan=1 colspan=1>156</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>17</td><td rowspan=1 colspan=1>143</td><td rowspan=1 colspan=1>160</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>157</td><td rowspan=1 colspan=1>160</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>95% CI</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>95% Cl</td></tr><tr><td rowspan=1 colspan=1>Sensitivity</td><td rowspan=1 colspan=1>16/23</td><td rowspan=1 colspan=1>69.6%</td><td rowspan=1 colspan=1>47.1-86.8%</td><td rowspan=1 colspan=1>2/4</td><td rowspan=1 colspan=1>50.0%</td><td rowspan=1 colspan=1>6.8-93.2%</td></tr><tr><td rowspan=1 colspan=1>Specificity</td><td rowspan=1 colspan=1>136/137</td><td rowspan=1 colspan=1>99.3%</td><td rowspan=1 colspan=1>96.0-100%</td><td rowspan=1 colspan=1>155/156</td><td rowspan=1 colspan=1>99.4%</td><td rowspan=1 colspan=1>96.5-100%</td></tr></table>

Sensitivity and Specificity by Age Relative to Culture - Fresh Nasopharyngeal Swab; Age 60   

<table><tr><td rowspan=1 colspan=1>Prospective FreshNasopharyngealSwab(Age ≥60)</td><td rowspan=1 colspan=3>RAMP Influenza A</td><td rowspan=1 colspan=3>RAMP Influenza B</td></tr><tr><td rowspan=1 colspan=1>Tissue Culture</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>14</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>3</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>152</td><td rowspan=1 colspan=1>154</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>166</td><td rowspan=1 colspan=1>167</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>154</td><td rowspan=1 colspan=1>170</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>167</td><td rowspan=1 colspan=1>170</td></tr><tr><td rowspan=1 colspan=1>Y</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>95% CI</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>95% CI</td></tr><tr><td rowspan=1 colspan=1>Sensitivity</td><td rowspan=1 colspan=1>14/16</td><td rowspan=1 colspan=1>87.5%</td><td rowspan=1 colspan=1>61.7-98.4%</td><td rowspan=1 colspan=1>2/3</td><td rowspan=1 colspan=1>66.7%</td><td rowspan=1 colspan=1>9.4-99.2%</td></tr><tr><td rowspan=1 colspan=1>Specificity</td><td rowspan=1 colspan=1>152/154</td><td rowspan=1 colspan=1>98.7%</td><td rowspan=1 colspan=1>95.4-99.8%</td><td rowspan=1 colspan=1>166/167</td><td rowspan=1 colspan=1>99.4%</td><td rowspan=1 colspan=1>96.7-100%</td></tr></table>

Sensitivity and Specificity by Age Relative to Culture - Fresh Wash/Aspirate; Age 0-5   

<table><tr><td rowspan=1 colspan=1>Prospective FreshNasalWash/Aspirate(Age 0-5)</td><td rowspan=1 colspan=3>RAMP Influenza A</td><td rowspan=1 colspan=3>RAMP Influenza B</td></tr><tr><td rowspan=1 colspan=1>Tissue Culture</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>24</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>28</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>6</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>117</td><td rowspan=1 colspan=1>123</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>144</td><td rowspan=1 colspan=1>145</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>121</td><td rowspan=1 colspan=1>151</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>144</td><td rowspan=1 colspan=1>151</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>95% CI</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>95% CI</td></tr><tr><td rowspan=1 colspan=1>Sensitivity</td><td rowspan=1 colspan=1>24/28</td><td rowspan=1 colspan=1>85.7%</td><td rowspan=1 colspan=1>67.3-96.0%</td><td rowspan=1 colspan=1>6/6</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>54.1-100%</td></tr><tr><td rowspan=1 colspan=1>Specificity</td><td rowspan=1 colspan=1>117/123</td><td rowspan=1 colspan=1>95.1%</td><td rowspan=1 colspan=1>89.7-98.2%</td><td rowspan=1 colspan=1>144/145</td><td rowspan=1 colspan=1>99.3%</td><td rowspan=1 colspan=1>96.2-100%</td></tr></table>

Sensitivity and Specificity by Age Relative to Culture - Fresh Wash/Aspirate; Age 6-21   

<table><tr><td rowspan=1 colspan=1>Prospective FreshNasalWash/Aspirate(Age 6-21)</td><td rowspan=1 colspan=3>RAMP Influenza A</td><td rowspan=1 colspan=3>RAMP Influenza B</td></tr><tr><td rowspan=1 colspan=1>Tissue Culture</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>17</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>3</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>41</td><td rowspan=1 colspan=1>46</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>59</td><td rowspan=1 colspan=1>60</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>17</td><td rowspan=1 colspan=1>46</td><td rowspan=1 colspan=1>63</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>59</td><td rowspan=1 colspan=1>63</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>95% Cl</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>95% Cl</td></tr><tr><td rowspan=1 colspan=1>Sensitivity</td><td rowspan=1 colspan=1>12/17</td><td rowspan=1 colspan=1>70.6%</td><td rowspan=1 colspan=1>44.0-89.7%</td><td rowspan=1 colspan=1>3/3</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>29.2-100%</td></tr><tr><td rowspan=1 colspan=1>Specificity</td><td rowspan=1 colspan=1>41/46</td><td rowspan=1 colspan=1>89.1%</td><td rowspan=1 colspan=1>76.4-96.4%</td><td rowspan=1 colspan=1>59/60</td><td rowspan=1 colspan=1>98.3%</td><td rowspan=1 colspan=1>91.1-100%</td></tr></table>

Sensitivity and Specificity by Age Relative to Culture - Fresh Wash/Aspirate; Age 22-59   

<table><tr><td rowspan=1 colspan=1>Prospective FreshNasalWash/Aspirate(Age 22-59)</td><td rowspan=1 colspan=3>RAMP Influenza A</td><td rowspan=1 colspan=3>RAMP Influenza B</td></tr><tr><td rowspan=1 colspan=1>Tissue Culture</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>3</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>3</td></tr><tr><td rowspan=1 colspan=1>canmaGentaYellowb</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>95% CI</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>95% CI</td></tr><tr><td rowspan=1 colspan=1>Sensitivity</td><td rowspan=1 colspan=1>0/0</td><td rowspan=1 colspan=1>NA</td><td rowspan=1 colspan=1>NA</td><td rowspan=1 colspan=1>0/0</td><td rowspan=1 colspan=1>NA</td><td rowspan=1 colspan=1>NA</td></tr><tr><td rowspan=1 colspan=1>Specificity</td><td rowspan=1 colspan=1>3/3</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>29.2-100%</td><td rowspan=1 colspan=1>3/3</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>29.2-100%</td></tr></table>

Sensitivity and Specificity by Age Relative to Culture - Fresh Wash/Aspirate; Age 60   

<table><tr><td rowspan=1 colspan=1>Prospective FreshNasalWash/Aspirate(Age ≥60)</td><td rowspan=1 colspan=3>RAMP Influenza A</td><td rowspan=1 colspan=3>RAMP Influenza B</td></tr><tr><td rowspan=1 colspan=1>Tissue Culture</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>1</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>1</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>95% CI</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>95% CI</td></tr><tr><td rowspan=1 colspan=1>Sensitivity</td><td rowspan=1 colspan=1>0/0</td><td rowspan=1 colspan=1>NA</td><td rowspan=1 colspan=1>NA</td><td rowspan=1 colspan=1>0/0</td><td rowspan=1 colspan=1>NA</td><td rowspan=1 colspan=1>NA</td></tr><tr><td rowspan=1 colspan=1>Specificity</td><td rowspan=1 colspan=1>1/1</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>NA</td><td rowspan=1 colspan=1>1/1</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>NA</td></tr></table>

Sensitivity and Specificity by Collection Type Relative to Culture - Fresh Nasopharyngeal Swab   

<table><tr><td rowspan=1 colspan=1>Prospective FreshNasopharyngealSwab</td><td rowspan=1 colspan=3>RAMP Influenza A</td><td rowspan=1 colspan=3>RAMP Influenza B</td></tr><tr><td rowspan=1 colspan=1>Tissue Culture</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>53</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>66</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>12</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>19</td><td rowspan=1 colspan=1>541</td><td rowspan=1 colspan=1>560</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>602</td><td rowspan=1 colspan=1>614</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>72</td><td rowspan=1 colspan=1>554</td><td rowspan=1 colspan=1>626</td><td rowspan=1 colspan=1>19</td><td rowspan=1 colspan=1>607</td><td rowspan=1 colspan=1>626</td></tr><tr><td rowspan=1 colspan=1>cYanmaGntYlowb</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>95% Cl</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>95% CI</td></tr><tr><td rowspan=1 colspan=1>Sensitivity</td><td rowspan=1 colspan=1>53/66</td><td rowspan=1 colspan=1>80.3%</td><td rowspan=1 colspan=1>68.7-89.1%</td><td rowspan=1 colspan=1>7/12</td><td rowspan=1 colspan=1>58.3%</td><td rowspan=1 colspan=1>27.7-84.8%</td></tr><tr><td rowspan=1 colspan=1>Specificity</td><td rowspan=1 colspan=1>541/560</td><td rowspan=1 colspan=1>96.6%</td><td rowspan=1 colspan=1>94.8-97.9%</td><td rowspan=1 colspan=1>602/614</td><td rowspan=1 colspan=1>98.0%</td><td rowspan=1 colspan=1>96.6-99.0%</td></tr></table>

Sensitivity and Specificity by Collection Type Relative to Culture - Fresh Wash/Aspirate   

<table><tr><td rowspan=1 colspan=1>Prospective FreshNasalWash/Aspirate</td><td rowspan=1 colspan=3>RAMP Influenza A</td><td rowspan=1 colspan=3>RAMP Influenza B</td></tr><tr><td rowspan=1 colspan=1>Tissue Culture</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>36</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>9</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>162</td><td rowspan=1 colspan=1>173</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>207</td><td rowspan=1 colspan=1>209</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>47</td><td rowspan=1 colspan=1>171</td><td rowspan=1 colspan=1>218</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>207</td><td rowspan=1 colspan=1>218</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>95% Cl</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>95% CI</td></tr><tr><td rowspan=1 colspan=1>Sensitivity</td><td rowspan=1 colspan=1>36/45</td><td rowspan=1 colspan=1>80.0%</td><td rowspan=1 colspan=1>65.4-90.4%</td><td rowspan=1 colspan=1>9/9</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>66.4-100%</td></tr><tr><td rowspan=1 colspan=1>Specificity</td><td rowspan=1 colspan=1>162/173</td><td rowspan=1 colspan=1>93.6%</td><td rowspan=1 colspan=1>88.9-96.8%</td><td rowspan=1 colspan=1>207/209</td><td rowspan=1 colspan=1>99.0%</td><td rowspan=1 colspan=1>96.6-99.9%</td></tr></table>

# Retrospective Testing

In order to supplement the prospective study, performance of the RAMP Influenza A/B Test was also evaluated by two independent laboratories comparing to the original cell culture testing results (cell cultures were performed originally using fresh specimens) on 75 retrospective frozen clinical nasopharyngeal swab samples and 130 retrospective frozen clinical wash/aspirate samples. The results of the retrospective clinical trials based on sample type are given in the following tables:

Retrospective Positive and Negative Percent Agreements by Collection Type Relative to Culture; Nasopharyngeal Swab   

<table><tr><td rowspan=1 colspan=1>RetrospectiveFrozenNasopharyngealSwab</td><td rowspan=1 colspan=3>RAMP Influenza A</td><td rowspan=1 colspan=3>RAMP Influenza B</td></tr><tr><td rowspan=1 colspan=1>Tissue Culture</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>23</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>30</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>62</td><td rowspan=1 colspan=1>62</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>45</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>64</td><td rowspan=1 colspan=1>75</td><td rowspan=1 colspan=1>23</td><td rowspan=1 colspan=1>52</td><td rowspan=1 colspan=1>75</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>95% CI</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>95% CI</td></tr><tr><td rowspan=1 colspan=1>Positive PercentAgreement</td><td rowspan=1 colspan=1>11/13</td><td rowspan=1 colspan=1>84.6%</td><td rowspan=1 colspan=1>54.5-98.1 %</td><td rowspan=1 colspan=1>23/30</td><td rowspan=1 colspan=1>76.7%</td><td rowspan=1 colspan=1>57.7-90.1%</td></tr><tr><td rowspan=1 colspan=1>Negative PercentAgreement</td><td rowspan=1 colspan=1>62/62</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>94.2-100%</td><td rowspan=1 colspan=1>45/45</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>92.1-100%</td></tr></table>

# Retrospective Positive and Negative Percent Agreements by Collection Type Relative to Culture; Wash / Aspirate

<table><tr><td rowspan=1 colspan=1>RetrospectiveFrozen NasalWash/Aspirate</td><td rowspan=1 colspan=3>RAMP Influenza A</td><td rowspan=1 colspan=3>RAMP Influenza B</td></tr><tr><td rowspan=1 colspan=1>Tissue Culture</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>35</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>33</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>39</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>83</td><td rowspan=1 colspan=1>85</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>89</td><td rowspan=1 colspan=1>91</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>37</td><td rowspan=1 colspan=1>93</td><td rowspan=1 colspan=1>130</td><td rowspan=1 colspan=1>35</td><td rowspan=1 colspan=1>95</td><td rowspan=1 colspan=1>130</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>95% CI</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>95% CI</td></tr><tr><td rowspan=1 colspan=1>Positive PercentAgreement</td><td rowspan=1 colspan=1>35/45</td><td rowspan=1 colspan=1>77.8%</td><td rowspan=1 colspan=1>62.9-88.8%</td><td rowspan=1 colspan=1>33/39</td><td rowspan=1 colspan=1>84.6%</td><td rowspan=1 colspan=1>69.5-94.1%</td></tr><tr><td rowspan=1 colspan=1>Negative PercentAgreement</td><td rowspan=1 colspan=1>83/85</td><td rowspan=1 colspan=1>97.6%</td><td rowspan=1 colspan=1>91.8-99.7%</td><td rowspan=1 colspan=1>89/91</td><td rowspan=1 colspan=1>97.8%</td><td rowspan=1 colspan=1>92.3-99.7%</td></tr></table>

# REFERENCES

1 Storch GA, Rapid diagnostic tests for influenza. Current Opinion in Pediatrics 2003, 15:77-84. 2 Lauer and Masters, Journal Clinical Microbiology, 1988 January; 26(1): 5456 Centers or Disease Control, Weekly Report:Influenza Summary Update, Week ending May 19, 2007 - Week 20

Mr. Ken Pilgrim   
Director - Quality/Regulatory   
Response Biomedical Corporation 100-8900 Glenlyon Parkway   
Burnaby, B.C.   
Canada V5J 5J8

# APR 1 6 2008

Re: k071591 Trade/Device Name: RAMP® Influenza A/B Assay Regulation Number: 21 CFR $\$ 866.3330$ Regulation Name: Influenza virus serological reagents Regulatory Class: I Product Code: GNX Dated: April $3 ^ { \mathrm { r d } }$ ,2008 Received: April ${ { 7 } ^ { \mathrm { { t h } } } }$ 2008

Dear Mr. Pilgrim:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class ⅡI (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

Page 2 -

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at 240-276-0450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at 240-276-3474. For questions regarding the reporting of device adverse events (Medical Device Reporting (MDR)), please contact the Division of Surveillance Systems at 240-276-3464. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its tol-free number (800) 638-2041 or (240) 276-3150 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

![](images/6622755efa9643bf9c1fa1c2b7551d4431842e5764e1d2b5815ca03c5566a8aa.jpg)

Sally A. Hojvat, M.Sc., Ph.D.   
Director   
Division of Microbiology Devices Office of In Vitro Diagnostic Device Evaluation and Safety   
Center for Devices and   
Radiological Health

# Enclosure

# Statement of Indications for Use

Indications for Use

510(k) Number (if known): K071591

Device Name: RAMP® Influenza A/B Assay

Indications for Use:

The RAMP® Influenza A/B Assay is a qualitative immunochromatographic assay used to identify the presence of Influenza A and Influenza B nucleoprotein antigens in nasal wash, nasal aspirate, nasopharyngeal aspirate, and nasopharyngeal swab specimens from symptomatic patients. It is an in vitro diagnostic assay that aids in the rapid differential diagnosis of influenza viral infections in symptomatic patients. A negative test is presumptive and it is recommended these results be confirmed by cell culture. Negative results do not preclude influenza virus infection and should not be used as the sole basis for treatment or other management decisions.

Concurrence of CDRH, Office of In Vitro Diagnostic Device Evaluation and Safety (OIVD)

Division Sign-Off lhne Sdef

Office of In Vitro Diagnostic Device Evaluation and Safety

510(k). k071591